First Citizens Bank & Trust Co. boosted its stake in shares of Mednax, Inc (NYSE:MD) by 56.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,019 shares of the company’s stock after buying an additional 2,879 shares during the period. First Citizens Bank & Trust Co.’s holdings in Mednax were worth $484,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of MD. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Mednax by 5.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $106,000 after buying an additional 77 shares in the last quarter. Ledyard National Bank increased its position in shares of Mednax by 19.0% in the first quarter. Ledyard National Bank now owns 1,725 shares of the company’s stock valued at $120,000 after buying an additional 275 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after buying an additional 55 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Mednax by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock valued at $139,000 after buying an additional 1,794 shares in the last quarter. Finally, Morgan Dempsey Capital Management LLC increased its position in shares of Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock valued at $157,000 after buying an additional 78 shares in the last quarter.

Mednax, Inc (MD) opened at 44.42 on Monday. The company has a market capitalization of $4.09 billion, a PE ratio of 14.15 and a beta of 0.40. The stock has a 50 day moving average of $57.29 and a 200-day moving average of $62.80. Mednax, Inc has a 12-month low of $43.88 and a 12-month high of $72.13.

Mednax (NYSE:MD) last posted its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $843 million for the quarter, compared to analyst estimates of $849.49 million. During the same quarter in the previous year, the firm earned $1.03 EPS. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. Equities analysts expect that Mednax, Inc will post $3.35 earnings per share for the current year.

WARNING: “First Citizens Bank & Trust Co. Boosts Position in Mednax, Inc (NYSE:MD)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/07/first-citizens-bank-trust-co-boosts-stake-in-mednax-inc-nysemd-updated.html.

MD has been the topic of several research analyst reports. TheStreet downgraded shares of Mednax from a “b-” rating to a “c+” rating in a report on Tuesday, May 16th. Stifel Nicolaus lowered their target price on shares of Mednax from $65.00 to $58.00 and set a “hold” rating on the stock in a report on Thursday, May 25th. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Thursday, April 27th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $58.00 price target on shares of Mednax in a research report on Wednesday, April 26th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $64.00.

In related news, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the completion of the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at approximately $16,300,845. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the sale, the director now directly owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.